Interim Report for the period April – June 2021

FDA grants Breakthrough Therapy designation for lecanemab Events during the second quarter 2021 · The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for lecanemab in Alzheimer’s disease, which is a program intended to facilitate and accelerate the development and review of drugs for serious or life-threatening conditions. Financial summary April – June 2021 · Net revenues for the period amounted to MSEK 7.3 (7.0) · Operating profit amounted to MSEK -33.8 (-37.9) · Profit for the period amounted to MSEK -34.2 (-38.2) and earnings per